These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10428317)

  • 21. Ovarian stimulation with human and recombinant gonadotropin - comparison of in vitro fertilization efficiency with use of time-lapse monitoring.
    Wdowiak A; Bojar I
    Reprod Health; 2015 Dec; 12():113. PubMed ID: 26667662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-down-regulated in-vitro fertilization patients.
    Jansen CA; van Os HC; Out HJ; Coelingh Bennink HJ
    Hum Reprod; 1998 Nov; 13(11):2995-9. PubMed ID: 9853844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delivery rates following IVF treatment, using two recombinant FSH preparations for ovarian stimulation.
    Harlin J; Aanesen A; Csemiczky G; Wramsby H; Fried G
    Hum Reprod; 2002 Feb; 17(2):304-9. PubMed ID: 11821268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment.
    Yong PY; Brett S; Baird DT; Thong KJ
    Fertil Steril; 2003 Feb; 79(2):308-15. PubMed ID: 12568839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What are the clinical benefits of recombinant gonadotrophins?: the development of recombinant FSH (Puregon((R))): a scientific business.
    Out HJ; Bennink HJ; de Laat WN
    Hum Reprod; 1999 Sep; 14(9):2189-90. PubMed ID: 10469679
    [No Abstract]   [Full Text] [Related]  

  • 26. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization.
    Out HJ; Mannaerts BM; Driessen SG; Bennink HJ
    Hum Reprod; 1995 Oct; 10(10):2534-40. PubMed ID: 8567765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation.
    Out HJ; Braat DD; Lintsen BM; Gurgan T; Bukulmez O; Gökmen O; Keles G; Caballero P; González JM; Fábregues F; Balasch J; Roulier R
    Hum Reprod; 2000 Jan; 15(1):29-35. PubMed ID: 10611184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Use of recombinant human luteinizing hormone for ovulation stimulation in in vitro fertilization-embryo transfer].
    Xu SR; Li Y; Liu H; Li HY; Tang R; Gao Q; Sheng Y; Chen ZJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Jun; 45(6):420-3. PubMed ID: 21029591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What are the clinical benefits of recombinant gonadotrophins? The good,the bad and the ugly.
    Hernández ER
    Hum Reprod; 1999 Jun; 14(6):1417-8. PubMed ID: 10357949
    [No Abstract]   [Full Text] [Related]  

  • 30. New gonadotropins for old?
    Lancet; 1992 Dec; 340(8833):1442-3. PubMed ID: 1360566
    [No Abstract]   [Full Text] [Related]  

  • 31. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of periovulatory luteinizing hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone.
    Esposito MA; Barnhart KT; Coutifaris C; Patrizio P
    Fertil Steril; 2001 Mar; 75(3):519-24. PubMed ID: 11239535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical use of recombinant gonadotropins (FSH, LH, hCG)].
    Antoine JM; Loumaye E; Alvarez S; Merviel P; Cornet D; Mandelbaum J; Salat-Baroux J
    Contracept Fertil Sex; 1997 Feb; 25(2):141-6. PubMed ID: 9116774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective, randomized study comparing highly purified urinary follicle-stimulating hormone (FSH) and recombinant FSH for in vitro fertilization/intracytoplasmic sperm injection in patients with polycystic ovary syndrome.
    Aboulghar M; Saber W; Amin Y; Aboulghar M; Mansour R; Serour G
    Fertil Steril; 2010 Nov; 94(6):2332-4. PubMed ID: 20188364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ovarian stimulation in women undergoing in-vitro fertilization and embryo transfer using recombinant human follicle stimulating hormone (Gonal-F) in non-down-regulated cycles.
    Strowitzki T; Kentenich H; Kiesel L; Neulen J; Bilger W
    Hum Reprod; 1995 Dec; 10(12):3097-101. PubMed ID: 8822421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First established pregnancy and birth after ovarian stimulation with recombinant human follicle stimulating hormone (Org 32489).
    Devroey P; Mannaerts B; Smitz J; Coelingh Bennink H; Van Steirteghem A
    Hum Reprod; 1993 Jun; 8(6):863-5. PubMed ID: 8345075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In Estimated Good Prognosis Patients Could Unexpected "Hyporesponse" to Controlled Ovarian Stimulation be Related to Genetic Polymorphisms of FSH Receptor?
    Alviggi C; Conforti A; Caprio F; Gizzo S; Noventa M; Strina I; Pagano T; De Rosa P; Carbone F; Colacurci N; De Placido G
    Reprod Sci; 2016 Aug; 23(8):1103-8. PubMed ID: 26902430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human menopausal gonadotropin and recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles.
    van Wely M; Westergaard LG; Bossuyt PM; van der Veen F
    Fertil Steril; 2003 Nov; 80(5):1121-2. PubMed ID: 14607560
    [No Abstract]   [Full Text] [Related]  

  • 40. Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. European Puregon Collaborative Anovulation Study Group.
    Coelingh Bennink HJ; Fauser BC; Out HJ
    Fertil Steril; 1998 Jan; 69(1):19-25. PubMed ID: 9457926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.